# Simris Group AB Agrees to 1.0 Million Euro Hammenhög Site Lease and Sale

- URL: https://stocks.freetheai.org/news/simris-group-ab-agrees-to-1-0-million-euro-hammenhog-site-lease-and-sale-6b75c7
- Published: 2026-10-07T14:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [OMXSTO:SIMRIS_B](https://stocks.freetheai.org/symbols/OMXSTO-SIMRIS_B)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Simris Group AB (OMXSTO:SIMRIS_B) has signed a memorandum of understanding to lease and subsequently sell its Hammenhög facility to Immunrise for 1.0 million euros. Under the agreement, Immunrise will take over the operating and routine maintenance costs of the facility immediately. Additionally, half of any rent paid before the sale is completed will offset the final purchase price. The buyer has been granted exclusivity until September 30, 2027.

This transaction supports the company's strategic pivot away from microalgae operations to focus on the development of oncology antibody-drug conjugates. By shifting the facility's routine maintenance and operating expenses to the buyer, the company expects to reduce its cash burn. Shares of Simris Group AB Class B rose 14.29% to 0.128 SEK following the announcement.

Investors should monitor whether Immunrise secures the necessary financing to complete the purchase, as the deal is contingent on funding, due diligence, and the execution of definitive agreements.

## Key points

- Simris Group AB signed an MoU to lease and sell its Hammenhög facility for 1.0 million euros.
- Immunrise will assume the facility's operating and maintenance costs, reducing Simris' cash burn.
- Half of the rent paid prior to the closing of the transaction will offset the final purchase price.
- The transaction is subject to Immunrise securing financing, due diligence, and final agreements.
- Simris Group AB is divesting the asset to focus on oncology antibody-drug conjugates.

## Questions and answers

### What is the agreed sale price for the Hammenhög facility?

Simris Group AB has set the sale price for the Hammenhög site at 1.0 million euros under the memorandum of understanding.

### Why is Simris Group AB selling the Hammenhög site?

The divestment allows Simris Group AB to exit its legacy microalgae operations and focus its resources on developing oncology antibody-drug conjugates.

### What conditions must be met to close the sale?

The transaction depends on Immunrise securing financing, completing due diligence, and both parties executing definitive agreements.